



**B**

Treatment	SUCRA	PrBest	Mean rank
GLP-1RA	74.9	30.1	3.5
DPP4i	74.7	12.5	3.5
TZD	73.8	27.5	3.6
Met	71.6	3.0	3.8
Placebo	63.6	8.9	4.6
Met+DPP4i	52.9	14.4	5.7
DPP4i+SGLT2i	41.7	3.4	6.8
Met+GLP-1RA	37.9	0.0	7.2
SU	31.6	0.0	7.8
SGLT2i	13.9	0.2	9.6
Met+TZD	13.6	0.0	9.6

**Supplementary Fig. 10.** Network geometry (A) and the results of rank test (B) for effect on triglyceride of antidiabetic treatments after 6 months. (A) Each circle represents an antidiabetic treatment that was included in the analysis, with the size of the circle proportional to the number of trials involving the treatment. The width of each connecting line is proportional to the number of subjects who participated in each pair of trials. The global test for inconsistency yielded a  $P$  value of 0.0038, which suggests that there may be significant inconsistencies present in the network of treatments. (B) The table presents the results of the network rank test (surface under the cumulative ranking curve [SUCRA], probability of being the best [PrBest], mean rank) for different antidiabetic treatments, ordered by mean rank. (C) Network (upper right side, gray zone) and pairwise (lower left side, white zone) meta-analytic results are depicted for effect on triglyceride (mg/dL) of antidiabetic treatments after 6 months. The outcome of meta-analysis is expressed as effect size with 95% credible intervals in the case of network meta-analysis and 95% confidence intervals in the case of pairwise meta-analysis. Each value and interval refer to the efficacy of the top row treatment compared to the left column. The order of antidiabetic treatments in this league table is presented in order of the mean rank results. TZD, thiazolidinedione; SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; DPP4i, dipeptidyl peptidase-4 inhibitor; Met, metformin; SU, sulfonyleurea. <sup>a</sup>Results indicate statistical significance.

(Continued to the next page)

Supplementary Fig. 10. Continued

C

	Met+TZD	SGLT2i	SU	Met+GLP-1RA	DPP4i+SGLT2i	Met+DPP4i	Placebo	Met	TZD	DPP4i	GLP-1RA
Met+TZD	Met+TZD	2.3 (-29.1 to 33.7)	-8.9 (-25.3 to 7.6)	-10.9 (-27.5 to 5.6)	-11.0 (-42.4 to 20.4)	-17.0 (-54.1 to 20.0)	-20.5 (-45.9 to 4.9)	-11.9 <sup>a</sup> (-18.9 to -4.9)	-26.4 (-55.7 to 3.0)	-24.3 <sup>a</sup> (-47.0 to -1.6)	-27.8 (-59.4 to 3.8)
SGLT2i		SGLT2i	-11.2 (-39.7 to 17.4)	-13.3 (-41.7 to 15.2)	-13.3 (-31.2 to 4.6)	-19.4 (-63.0 to 24.3)	-22.8 (-53.3 to 7.7)	-11.9 (-39.4 to 15.7)	-28.7 (-66.1 to 8.7)	-26.6 (-48.3 to -4.9)	-30.2 (-69.3 to 9.0)
SU			SU	-2.1 (-12.3 to 8.1)	-2.1 (-30.7 to 26.4)	-8.2 (-42.9 to 26.5)	-11.7 (-33.5 to 10.2)	20.0 (-23.8 to 63.9)	-17.5 (-43.8 to 8.8)	-15.4 (-34.1 to 3.2)	-19.0 (-47.8 to 9.8)
Met+GLP-1RA				Met+GLP-1RA	-0.1 (-28.5 to 28.4)	-6.1 (-40.7 to 28.5)	-9.6 (-31.3 to 12.1)	-5.8 (-39.7 to 28.1)	-15.4 (-41.6 to 10.8)	-13.4 (-31.8 to 5.1)	-16.9 (-45.6 to 11.8)
DPP4i+SGLT2i		13.3 (-4.1 to 30.7) <i>I</i> <sup>2</sup> =0.0% 1 study			DPP4i+SGLT2i	-6.1 (-49.7 to 37.6)	-9.5 (-40.0 to 21.0)	-22.8 (-37.8 to -7.9)	-15.4 (-52.8 to 22.0)	-13.3 (-35.0 to 8.4)	-16.9 (-56.0 to 22.3)
Met+DPP4i						Met+DPP4i	-3.5 (-43.1 to 36.2)	12.9 (-24.9 to 50.7)	-9.3 (-51.6 to 32.9)	-7.3 (-45.2 to 30.7)	-10.8 (-54.6 to 33.0)
Placebo		-11.7 <sup>a</sup> (-18.7 to -4.8) <i>I</i> <sup>2</sup> =0.0% 5 studies				-9.5 (-30.3 to 11.3) <i>I</i> <sup>2</sup> =0.0% 1 study	Placebo	1.5 (-15.6 to 18.5)	-5.9 (-38.4 to 26.7)	-3.8 (-25.3 to 17.7)	-7.3 (-41.9 to 27.2)
Met	14.1 (1.7 to 26.5) <i>I</i> <sup>2</sup> =74.9% 3 studies		13.3 <sup>a</sup> (7.6 to 19.0) <i>I</i> <sup>2</sup> =0.0% 3 studies	11.9 <sup>a</sup> (6.3 to 17.5) <i>I</i> <sup>2</sup> =0.0% 1 study		-4.6 (-19.3 to 10.0) <i>I</i> <sup>2</sup> =0.0% 2 studies	-2.1 (-20.3 to 16.1) <i>I</i> <sup>2</sup> =0.0% 2 studies	Met	-5.0 (-32.8 to 22.8)	-37.0 <sup>a</sup> (-66.8 to -7.2)	-6.7 (-27.4 to 14.0)
TZD	-10.6 (-36.4 to 15.2) <i>I</i> <sup>2</sup> =0.0% 1 study		15.7 <sup>a</sup> (10.1 to 21.4) <i>I</i> <sup>2</sup> =58.1% 3 studies				-8.9 (-45.7 to 27.9) <i>I</i> <sup>2</sup> =0.0% 1 study	11.5 <sup>a</sup> (7.8 to 15.3) <i>I</i> <sup>2</sup> =81.7% 5 studies	TZD	2.1 (-28.4 to 32.6)	-1.5 (-39.0 to 36.1)
DPP4i		14.1 (-1.6 to 29.9) <i>I</i> <sup>2</sup> =65.7% 2 studies			13.3 (-8.0 to 34.6) <i>I</i> <sup>2</sup> =0.0% 1 study	-5.6 (-22.9 to 11.7) <i>I</i> <sup>2</sup> =0.0% 1 study	9.9 (-0.3 to 20.2) <i>I</i> <sup>2</sup> =20.8% 7 studies	6.2 (-3.0 to 15.5) <i>I</i> <sup>2</sup> =0.0% 3 studies		DPP4i	-3.6 (-36.2 to 29.1)
GLP-1RA								5.0 (-22.5 to 32.5) <i>I</i> <sup>2</sup> =0.0% 1 study			GLP-1RA